Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer
Xin Cheng, Yadong Zhang, Changli Qian, Erica Holdridge et autres
0 citationsNature Communications
Elena V. Ivanova
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
279Publications signalées
16514Citations signalées
3Affiliations récentes
Institutions déclarées
Domaines associés
interferon and immune responsesCAR-T cell therapy researchCytokine Signaling Pathways and InteractionsLung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Publications récentes
Table S1 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Takahiko Murayama, Navin R. Mahadevan, Catherine B. Meador, Elena V. Ivanova et autres
0 citations
Table S2 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Takahiko Murayama, Navin R. Mahadevan, Catherine B. Meador, Elena V. Ivanova et autres
0 citations
Editorial Expression of Concern: Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells
Takeshi Fujiwara, Madhavi Bandi, Masayuki Nitta, Elena V. Ivanova et autres
0 citationsNature
Data from Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors
Alberto Hernando‐Calvo, Richard D. Carvajal, Paul K. Paik, Van K. Morris et autres
0 citations
Supplementary Table 2 from Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors
Alberto Hernando‐Calvo, Richard D. Carvajal, Paul K. Paik, Van K. Morris et autres
0 citations
Supplementary Text 1 from Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors
Alberto Hernando‐Calvo, Richard D. Carvajal, Paul K. Paik, Van K. Morris et autres
0 citations
Supplementary Table 1 from Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors
Alberto Hernando‐Calvo, Richard D. Carvajal, Paul K. Paik, Van K. Morris et autres
0 citations
Supplementary Figure 1 from Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors
Alberto Hernando‐Calvo, Richard D. Carvajal, Paul K. Paik, Van K. Morris et autres
0 citations
Supplementary Figure 2 from Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors
Alberto Hernando‐Calvo, Richard D. Carvajal, Paul K. Paik, Van K. Morris et autres
0 citations
Supplementary Table 3 from Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors
Alberto Hernando‐Calvo, Richard D. Carvajal, Paul K. Paik, Van K. Morris et autres
0 citations
Supplementary Text 2 from Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors
Alberto Hernando‐Calvo, Richard D. Carvajal, Paul K. Paik, Van K. Morris et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.